๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

23 recruiting trials

for OligoProgressive Metastatic Disease

A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases NCT04299646Phase 230 sites๐Ÿ“ Albi๐Ÿ“ Angers๐Ÿ“ Bordeaux Centre Francois Baclesse ยท Tests: Steretactic radiotherapy Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer NCT06260033Phase 22 sites๐Ÿ“ Duarte๐Ÿ“ Irvine City of Hope Medical Center ยท Tests: Biospecimen Collection, Bone Scan, Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions NCT07883798n/a1 site๐Ÿ“ Zamoล›ฤ‡ Affidea Nu-med Center of Oncological DIagnostics and Therapy ยท Tests: Routine-care metastasis-directed radiotherapy PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer NCT07691697n/a1 site๐Ÿ“ Zamoล›ฤ‡ Affidea Nu-med Center of Oncological DIagnostics and Therapy ยท Tests: Comprehensive Progression-Directed Radiotherapy SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy NCT06676722Phase 22 sites๐Ÿ“ Xiamen๐Ÿ“ Xiamen The First Affiliated Hospital of Xiamen University ยท Tests: SBRT combined with Nimotuzumab followed by Tislelizumab A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab NCT07619599Phase 11 site๐Ÿ“ Duarte City of Hope Medical Center ยท Tests: Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomoโ€ฆ Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer NCT06927635Phase 21 site๐Ÿ“ Toronto University Health Network, Toronto ยท Tests: Stereotactic Body Radiation Therapy (SBRT), Systemic therapy A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP) NCT06367972Phase 2, Phase 31 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Local Consolidation Therapy, Next-line Systemic Therapy Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer NCT04989725Phase 21 site๐Ÿ“ Montreal Centre hospitalier de l'Universitรฉ de Montrรฉal (CHUM) ยท Tests: Standard arm, Experimental arm Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast) NCT06925984NA5 sites๐Ÿ“ Brussels๐Ÿ“ Ghent๐Ÿ“ Kortrijk Jules Bordet Institute ยท Tests: SBRT Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma NCT04974671Phase 21 site๐Ÿ“ New Haven Yale University ยท Tests: Stereotactic Body Radiation Therapy Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer NCT06686771Phase 375 sites๐Ÿ“ Phoenix๐Ÿ“ Duarte๐Ÿ“ Irvine Canadian Cancer Trials Group ยท Tests: SBRT, First or second-line standard of care therapy Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma NCT07112170NA1 site๐Ÿ“ Toronto University Health Network, Toronto ยท Tests: Stereotactic Body Radiation Therapy (SBRT) Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer NCT04838899NA1 site๐Ÿ“ Toronto Sunnybrook Health Sciences Centre ยท Tests: Stereotactic Body Radiation Therapy (SABR) Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers NCT06918951NA1 site๐Ÿ“ Surrey British Columbia Cancer Agency ยท Tests: Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy Stereotactic Magnetic Resonance Guided Radiation Therapy NCT04115254NA2 sites๐Ÿ“ Boston๐Ÿ“ Boston Dana-Farber Cancer Institute ยท Tests: MR-guided Linac Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC NCT06841172Phase 31 site๐Ÿ“ Jinan Shandong Cancer Hospital and Institute ยท Tests: radiotherapy, Systemic therapy (Continuation of current first-line systemic therapy), Systemic therapy (Early switch toโ€ฆ Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer NCT06601296Phase 21 site๐Ÿ“ Dallas University of Texas Southwestern Medical Center ยท Tests: IMSA101 Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation. NCT05102747NA15 sites๐Ÿ“ Bordeaux๐Ÿ“ Bordeaux๐Ÿ“ Brest Centre Francois Baclesse ยท Tests: Hypofractionated SRT (stereotactic radiotherapy), Historical single-dose SRS (stereotactic radiosurgery) Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer NCT06523673Phase 31 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Stereotactic Body Radiotherapy, second-line systemic therapy COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study NCT05301881Phase 27 sites๐Ÿ“ Alkmaar๐Ÿ“ Amsterdam๐Ÿ“ Arnhem The Netherlands Cancer Institute ยท Tests: Surgery, Radiotherapy, Radiofrequent ablation The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC) NCT07038304Phase 22 sites๐Ÿ“ Groningen๐Ÿ“ Nijmegen University Medical Center Groningen ยท Tests: Metastasis directed radiotherapy Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression NCT05784428NA14 sites๐Ÿ“ Kelowna๐Ÿ“ Prince George๐Ÿ“ Surrey Robert Olson ยท Tests: Single fraction SABR, Multiple fraction SABR, QoL reporting alone, QoL reporting, symptom screen and healthcare provideโ€ฆ
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy